Related Experiment Video
Updated: Jun 11, 2026

Expression and Purification of Virus-like Particles for Vaccination
Published on: June 2, 2016
Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine
Toon Stegmann1, Tobias Kamphuis, Tjarko Meijerhof
1Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen and University of Groningen, 9700 RB, Groningen, The Netherlands.
Abstract:
Respiratory syncytial virus (RSV) causes severe respiratory disease in children and the elderly. There is no registered RSV vaccine. Early experimental non-replicating vaccines have been found to exacerbate RSV symptoms upon infection causing enhanced respiratory disease. Here we show that immunization of mice with reconstituted virosomes produced from RSV envelopes and containing the lipopeptide adjuvant (P3CSK4), induces high-titer virus-neutralizing antibodies, and the secretion of IFN-gamma through both MHC-I and MHC-II presentation of antigen, with a balanced Th1/Th2 profile. Immunization with RSV virosomes provides sterilizing immunity to virus challenge in mice and cotton rats, while not producing symptoms of enhanced disease. Therefore, these virosomes represent a promising candidate inactivated RSV vaccine formulation.
Related Concept Videos
Respiratory Syncytial Virus Disease
Poliomyelitis
Vaccine Production
Vaccines
Microorganisms in Medicine and Therapeutics

